SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Artal Group S.A.

CIK 0001053906 · VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, N4, L-2661 · (352) 22.42.59-1

Reported Value
$3M
Q4 2023
Positions
98
Filings on Record
31
2019–present window
Filed
Feb 9, 2024
original filing

Summary

Artal Group S.A. reported $3M in U.S.-listed holdings across 98 positions for Q4 2023.

The portfolio is heavily concentrated: CAVA alone accounts for 45.7% of reported value.

Compared with Q3 2023, the fund opened 15 new positions and exited 24.

Portfolio Metrics

Turnover
+13.0%
vs prior filed quarter
Top-10 Concentration
+75.1%
share of reported value
Largest Position
+45.7%
Cava
New / Exited
15 / 24
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.7BQ4 ’18Q1 ’19: $2.4BQ2 ’19: $2.5BQ3 ’19: $2.5BQ4 ’19: $2.6BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $4.1BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $5.7BQ2 ’21: $4.9BQ3 ’21: $4.5BQ4 ’21: $3.7BQ4 ’21Q1 ’22: $2.4BQ2 ’22: $1.9BQ3 ’22: $2.3BQ1 ’23: $2MQ1 ’23Q2 ’23: $3MQ3 ’23: $2MQ4 ’23: $3MQ2 ’24: $3.9BQ2 ’24Q3 ’24: $2.4BQ4 ’24: $1.2BQ1 ’25: $884MQ2 ’25: $930MQ2 ’25Q3 ’25: $758MQ4 ’25: $715MQ1 ’26: $1.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 89.5%ADR: 7.2%Other: 3.3%
  • Common Stock · 89.5% · $3M
  • ADR · 7.2% · $217,472
  • Other · 3.3% · $98,903

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ARGXARGENX SENEW+116.4K116.4K+$44,277$44,277
KRROKORRO BIO INCNEW+418.6K418.6K+$20,064$20,064
PROTHENA CORP PLCNEW+501.4K501.4K+$18,219$18,219
LXEOLEXEO THERAPEUTICS INCNEW+603.4K603.4K+$8,098$8,098
260CENTESSA PHARMACEUTICALS PLCNEW+1.01M1.01M+$8,060$8,060
CYMABAY THERAPEUTICS INCNEW+303.6K303.6K+$7,171$7,171
PDDPDD HOLDINGS INCNEW+32.5K32.5K+$4,755$4,755
GPCRSTRUCTURE THERAPEUTICS INCNEW+86.6K86.6K+$3,530$3,530

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

46 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CAVACAVA GROUP INChistory →COM45.73%$1M32.01M
2SRRKSCHOLAR ROCK HLDG CORPhistory →COM7.04%$211,67711.26M
3LXRXLEXICON PHARMACEUTICALS INChistory →COM NEW5.98%$179,857117.55M
4CYTKCYTOKINETICS INChistory →COM NEW3.37%$101,3811.21M
5APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM2.83%$85,0821.42M
6ONCBEIGENE LTDhistory →SPONSORED ADR2.43%$72,952404.5K
7KYMRKYMERA THERAPEUTICS INChistory →COM2.14%$64,4332.53M
8MORFUSDMORPHIC HLDG INChistory →COM2.05%$61,7512.14M
9SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM1.96%$58,9601.62M
10SLNSILENCE THERAPEUTICS PLChistory →ADS1.73%$52,1103.00M
11RVMDREVOLUTION MEDICINES INChistory →COM1.62%$48,6401.70M
12ARGXARGENX SEhistory →SPONSORED ADR1.47%$44,277116.4K
13NMRANEUMORA THERAPEUTICS INChistory →COM1.45%$43,5242.55M
14ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.05%$31,4651.03M
15AM6AMICUS THERAPEUTICS INCCOM0.96%$28,7542.03M
161K0IGM BIOSCIENCES INCCOM0.86%$25,7653.10M
17KURAKURA ONCOLOGY INCCOM0.85%$25,4251.77M
18ACELYRIN INCCOM0.75%$22,6483.04M
19GLYCEURGLYCOMIMETICS INCCOM0.67%$20,2708.59M
20KRROKORRO BIO INCCOM0.67%$20,064418.6K
21SYROS PHARMACEUTICALS INCCOM NEW0.65%$19,5142.51M
22PROTHENA CORP PLCSHS0.61%$18,219501.4K
23DNLIDENALI THERAPEUTICS INCCOM0.57%$17,230802.9K
24DYNDYNE THERAPEUTICS INCCOM0.54%$16,1991.22M
25WAVE LIFE SCIENCES LTDSHS0.50%$15,1873.01M
26SESEA LTDSPONSORED ADS0.50%$15,066372.0K
27HARPUSDHARPOON THERAPEUTICS INCCOM NEW0.49%$14,8281.30M
28AGENEURAGENUS INCCOM NEW0.43%$12,94115.63M
29NTRANATERA INCCOM0.42%$12,528200.0K
30ROIVANT SCIENCES LTDSHS0.37%$11,2301.00M
31GOSSGOSSAMER BIO INCCOM0.37%$11,00412.06M
32SDGRSCHRODINGER INCCOM0.36%$10,740300.0K
33ERASERASCA INCCOM0.33%$10,0564.72M
34FUSION PHARMACEUTICALS INCCOM0.32%$9,6631.01M
35SEERSEER INCCOM CL A0.31%$9,2154.75M
36LXEOLEXEO THERAPEUTICS INCCOM0.27%$8,098603.4K
37260CENTESSA PHARMACEUTICALS PLCSPONSORED ADS0.27%$8,0601.01M
38OVIDOVID THERAPEUTICS INCCOM0.27%$8,0502.50M
39CYMABAY THERAPEUTICS INCCOM0.24%$7,171303.6K
40TSMTAIWAN SEMICONDUCTOR MFG LTDSPONSORED ADS0.24%$7,07268.0K
41TSHATAYSHA GENE THERAPIES INCCOM SHS0.22%$6,4843.66M
42CARTESIAN THERAPEUTICS INCCOM0.21%$6,2999.14M
43VIGLVIGIL NEUROSCIENCE INCCOM0.20%$6,1221.81M
44BDTXBLACK DIAMOND THERAPEUTICS ICOM0.19%$5,7512.05M
45SLDBSOLID BIOSCIENCES INCCOM NEW0.19%$5,583909.2K
46VOR BIOPHARMA INCCOM0.18%$5,2822.35M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.0B2May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$715M2Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$758M2Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$930M2Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$884M2May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.2B2Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.4B2Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.9B114Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024under review113May 17, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$3M98Feb 9, 202413F-HRchanges · EDGAR ↗
Q3 2023$2M105Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$3M119Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$2M120May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022under review131Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.3B137Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.9B137Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.4B139May 12, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.7B152Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.5B148Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$4.9B146Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$5.7B148May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B132Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$4.1B137Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B134Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B105May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.6B99Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B109Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.5B109Aug 9, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.4B110May 10, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.7B108Feb 11, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 5 additional managers.

  • Stichting Administratiekantoor Westend028-15028
  • Westend S.A.028-15029
  • Artal International Management S.A.028-15031
  • Artal International S.C.A.028-15033
  • Invus Public Equities Advisors, LLC028-11522

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.